How It Works
When ordering a CCTA for patients, clinicians can include Heartflow Plaque Analysis to enhance their diagnostic confidence and potentially improve patient outcomes through tailored treatment strategies.
Plaque Analysis: Reveal the True Plaque Burden
Heartflow's Plaque Analysis represents a significant advancement in proactive care for CAD. As a non-invasive, AI-enabled disease management tool, it provides clinicians a better path towards accurate risk assessment and personalized care.
Helping You DECIDE What’s Right For Your Patients
DECIDE is the largest prospective registry on Plaque Analysis in CAD, demonstrating how Plaque Analysis with Heartflow Plaque Staging* empowers physicians with clinical insights that lead to real-world impact.
What if 50% of your CCTA patients could benefit from an adjustment to their treatment plan?
Plaque Analysis identifies and quantifies all plaque types, providing you with personalized data and Plaque Staging* insights to determine which 50% of your patients require changes to their treatment plans.
Actionable
Achieve better treatment decisions earlier to reduce risk and adverse events associated with cardiovascular disease.
7x risk of major cardiac event
Patients in a high total plaque volume cohort
have a 7x risk of a major cardiac event
compared to the low plaque volume cohort.2
Nearly 1/3 Patients
with 0 calcified plaque had a change in management1
More than 50%
of patients had their medical management changed when Plaque Analysis with Plaque Staging* was added compared to their management based on CCTA alone.1
Accurate
Demonstrated accuracy in quantifying and characterizing coronary plaque so clinicians can be confident in their diagnosis and management.
95% agreement
agreement with IVUS in precisely quantifying and characterizing coronary plaque.3
Comprehensive
Quantifies calcified, non-calcified, and low attenuation plaque to help clinicians assess extent of CAD risk and provide personalized treatment.
The interactive model provides:
- Plaque location by vessel with quantification by vessel territory
- Accurate plaque volume across calcified, non-calcified and low attenuation
- Co-registered cross-sections of vessels with sCPR and type of plaque
FFRCT values available when performed
Plaque Analysis in
Heartflow One
Current methods of assessing patient CAD risk, including risk scores and other surrogate markers, are leaving patients under-treated. Plaque quantification is the only tool to accurately assess overall plaque burden to drive personalized treatment for improved outcomes.
Heartflow One Integrated Workflow
1
CCTA performed, then automatically and securely sent to Heartflow
2
Heartflow AI enabled analysis of anatomy and physiology
3
All available analysis delivered*
4
Analysis automatically delivered to PACS and EMR
Median Turnaround Time is 90 minutes
[Plaque Analysis] can actually help guide our treatment by identifying high risk plaque components…It’s treating the whole patient and their overall risk, not just the one component of that risk.
”
Discover how you can use Heartflow to advance your approach to coronary artery disease diagnosis, treatment and management.